Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$3.87 USD
-0.43 (-10.00%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $3.86 -0.01 (-0.26%) 6:16 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fate Therapeutics (FATE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.57 | $12.00 | $5.00 | 76.05% |
Price Target
Based on short-term price targets offered by 14 analysts, the average price target for Fate Therapeutics comes to $7.57. The forecasts range from a low of $5.00 to a high of $12.00. The average price target represents an increase of 76.05% from the last closing price of $4.30.
Analyst Price Targets (14)
Broker Rating
Fate Therapeutics currently has an average brokerage recommendation (ABR) of 2.57 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 21 brokerage firms. The current ABR compares to an ABR of 2.57 a month ago based on 21 recommendations.
Of the 21 recommendations deriving the current ABR, six are Strong Buy, representing 28.57% of all recommendations. A month ago, Strong Buy represented 28.57%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 13 | 13 | 13 | 13 | 13 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.57 | 2.57 | 2.57 | 2.57 | 2.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/23/2024 | Wedbush Securities | David M Nierengarten | Hold | Hold |
4/11/2024 | Needham & Company | Gil J Blum | Hold | Hold |
3/1/2024 | H.C. Wainwright & Co. | Robert Burns | Hold | Hold |
2/27/2024 | BMO Capital Markets | Etzer Darout | Hold | Hold |
2/27/2024 | Cantor Fitzgerald & Co | Li Watsek | Hold | Hold |
12/1/2023 | Guggenheim Securities | Michael Schmidt | Hold | Hold |
11/29/2023 | Robert W. Baird & Co. | Jack K Allen | Hold | Hold |
9/28/2023 | SVB Securities | Daina M Graybosch | Strong Buy | Strong Buy |
9/15/2023 | Canaccord Genuity | William Maughan | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.57 |
ABR (Last week) | 2.57 |
# of Recs in ABR | 21 |
Average Target Price | $7.57 |
LT Growth Rate | 7.90% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 69 of 252 |
Current Quarter EPS Est: | -0.48 |